The National Agency for Food and Drug Administration and Control (NAFDAC) has announced that it will certify and approve every drug manufactured under the National Health Insurance Authority (NHIA) branded medicines initiative, ensuring their quality, safety, and efficacy…CONTINUE READING....KINDLY READ THE FULL STORY HERE▶
Prof. Mojisola Adeyeye, the Director-General of NAFDAC, made this statement during a joint press briefing held in Abuja in collaboration with NHIA.
She further mentioned that these medicines will undergo testing in the WHO-Prequalified NAFDAC Laboratory. As part of its Post Marketing Surveillance activities, NAFDAC will continuously monitor and ensure that these branded medicines are exclusively used in the country’s healthcare facilities and are not available for general retail.
Recently, the NHIA entered into a Memorandum of Understanding (MoU) with 12 pharmaceutical companies and Drugs Management Organisations (DMOs) to produce 33 different drugs, addressing the persistent issue of drug shortages in the nation’s healthcare facilities.
Prof. Adeyeye stressed that the initiative also aims to bolster local pharmaceutical manufacturers, ultimately ensuring the security of medicines.
She highlighted that NAFDAC has been actively involved in this effort over the past five years, focusing on making pharmaceutical manufacturing facilities fit for purpose. This proactive approach will contribute to reducing the prevalence of substandard and counterfeit medical products.
